MARKETSnap
  • Gainers &
    Losers
  • Most Active &
    More
  • 52-Week
    High/Low
  • P/E
    Ratios
    • Large Caps
    • Absolute
    • Total Market PE
  • Stocks
    Performance
    • Large Caps
    • Absolute
  • Industries
    Performance
    • Industry
    • Sector
  • Dividends
  • 📅 Calendar
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 🔧 Tools
    • 💰 Intrinsic Value Calculator
    • 📈 Compounding Calculator
    • 🤖 Stock Pick Screener
  • More
    • Charts
    • Investment Compounding Calculator
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
OMCL stock logo

OMCL

Omnicell, Inc.

$41.49
0.49
 (1.2%)
Exchange:  NASDAQ
Market Cap:  1.887B
Shares Outstanding:  1.704M
Delayed data
Calculate OMCL Intrinsic Value
5-year outlook →
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  Healthcare
Industry:  Medical – Equipment & Services
   
CEO:  Randall A. Lipps
Full Time Employees:  3525
Address: 
4220 North Freeway
Fort Worth
TX
76137
US
Website:  https://www.omnicell.com
Omnicell, Inc., together with its subsidiaries, provides healthcare technology in the United States and internationally. It offers hospital and health systems solutions, such as points of care for clinician workflows in patient care areas of the healthcare system; Titan XT, an automated dispensing system; XTExtend, a console swap for its XT cabinets; and Central Pharmacy Dispensing Service for the medication dispensing process. The company also provides Central Med Automation Service for medication dispensing; IV Compounding Service, an in-house compounding system; specialty pharmacy services, including turnkey solution to help health systems establish, manage, and optimize an entity-owned specialty pharmacy; EnlivenHealth platform to digitally enable retail and community pharmacies; medication adherence solutions comprising consumables and medication packaging systems; and technology implementation, customer education and training, program management, and related offerings to professional services. In addition, it offers post-installation support and maintenance via phone and/or web, on-site service, parts, and access to software upgrades; software and hardware products for full traceability of medicines and medical supplies throughout the healthcare system; OmniSphere, a cloud-based platform. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Fort Worth, Texas.

Click to read more…

Revenue Segmentation

MARKETSnap
MARKETSnap

Log in to continue

Log in to see the complete revenue and geographic breakdown.

Login — it's free

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Login — it's free
View full analyst estimates

Earnings Call

Full text

Earnings transcript

Read the complete earnings call transcript.

AI summary

Key takeaways

Short, structured highlights from the call so you can focus on what matters.

2026/04/28 — Q1 quarter 2026

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Login — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue1,147,1121,112,2381,184,845
Gross Profit499,929471,003508,043
EBITDA79,979119,873101,869
Operating Income-19,32933711,665
Net Income-20,37112,5312,052

Log in to continue

Log in to see the income statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets2,226,8782,120,9601,974,720
Total Liabilities1,037,924877,647742,906
Total Stockholders Equity1,188,9541,243,3131,231,814
Total Debt614,090382,546192,390
Cash and Cash Equivalents467,972369,201196,520

Log in to continue

Log in to see the balance sheet and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow181,094187,722127,300
Capital Expenditure-55,016-36,463-40,415
Free Cash Flow126,078151,25986,885
Net Income-20,37112,5312,052
Net Change in Cash148,144-102,365-147,582

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2028Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Low)1,381,771.251Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (High)1,456,428.748Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Avg)1,419,100Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Low)135,777.896Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (High)143,114.015Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Avg)139,445.956Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Low)104,483.723Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (High)108,926.130Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Avg)105,500Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Low)491,194.478Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (High)517,733.857Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Avg)504,464.167Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Avg)2.300Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (High)2.350Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Low)2.250Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated Revenue)2Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated EPS)1Research AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in and subscribe to Full Access to see up to 5 years of analyst estimates.

Login — it's free

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
1.112B  ?P/S
 (TTM)
: 
1.52
?Net Income
 (TTM)
: 
12.531M  ?P/E
 (TTM)
: 
92.16
?Enterprise Value
 (TTM)
: 
1.776B  ?EV/FCF
 (TTM)
: 
15.89
?Dividend Yield
 (TTM)
: 
0%  ?Payout Ratio
 (TTM)
: 
0%
?ROE
 (TTM)
: 
1.64%  ?ROIC
 (TTM)
: 
1.22%
?Net Debt
 (TTM)
: 
-16068000  ?Debt/Equity
 (TTM)
: 
0.16
?P/B
 (TTM)
: 
1.48  ?Current Ratio
 (TTM)
: 
1.46

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Login — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Research Access for high/low estimates and the interactive table.

Forward P/E 1YResearch AccessResearch AccessResearch AccessResearch Access
21.39Research AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in with Full Access for forward P/E high/low estimates and the full multi-year table.

Login — it's free

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

Based on current fundamentals and analyst forecasts, MARKETSnap estimates OMCL intrinsic value between $48.12 – $133.50 per share. This depends on revenue growth, margins, and discount rate.

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.

[intrinsic_calculator]

Common questions about OMCL valuation

Is Omnicell, Inc. (OMCL) overvalued or undervalued right now?

MARKETSnap estimates intrinsic value for Omnicell, Inc. (OMCL) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is OMCL a buy, hold, or sell for long-term investors?

MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether OMCL trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is OMCL’s P/E ratio?

You can see OMCL’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for OMCL?

MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is OMCL a good long-term investment?

Whether OMCL fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

OMCL

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

Daily snapshot

1.2
MARKETSnap

Trading Metrics:

Open: 41.75   Previous Close: 41
Day Low: 40.86   Day High: 42.35
Year Low: 28.09   Year High: 55
Price Avg 50: 42.47   Price Avg 200: 40.12
Volume: 818246   Average Volume: 696574

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Login — it's free
See in Nexus

Relevant news

OMCL or HIMS: Which Is the Better Value Stock Right Now?
26-06-2026 12:40
OMCL or HIMS: Which Is the Better Value Stock Right Now?
Omnicell, Inc. (OMCL) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
09-06-2026 17:32
Omnicell, Inc. (OMCL) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Omnicell (OMCL) Up 0.1% Since Last Earnings Report: Can It Continue?
28-05-2026 12:36
Omnicell (OMCL) Up 0.1% Since Last Earnings Report: Can It Continue?
Omnicell Stock Surges 57.3% in a Year: What's Driving It?
25-05-2026 10:06
Omnicell Stock Surges 57.3% in a Year: What's Driving It?
Omnicell, Inc. (OMCL) Shareholder/Analyst Call Prepared Remarks Transcript
19-05-2026 18:00
Omnicell, Inc. (OMCL) Shareholder/Analyst Call Prepared Remarks Transcript
Omnicell (OMCL) is a Great Momentum Stock: Should You Buy?
05-05-2026 13:01
Omnicell (OMCL) is a Great Momentum Stock: Should You Buy?

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States

Language

  • Gainers & Losers
  • Most Active & More
  • 52-Week High/Low
  • Dividends
    • Large Caps
    • Absolute
    • Total Market PE
    • Large Caps
    • Absolute
    • Industry
    • Sector
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 💰 Stock intrinsic value Calculator
  • 📈 Investment Compounding Calculator
  • 🤖 Stock Pick Screener
  • 📋 Watchlist & Portfolio
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Nexus
  • Login Login
  • Profile Profile
  • Watchlist & Portfolio Watchlist & Portfolio
  • My Valuations My Valuations
  • Settings Settings

Media

Watch Listen Read